About Sermorelin Doctor.

What this site is

Sermorelin Doctor is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "Doctor" in the name is editorial framing, not a claim about services. It names a position the publisher occupies relative to the literature — the measured, reference-monograph register of a work that reads the studies carefully — not a physician, a clinic, or a prescriber. There are no doctors here to consult, no treatment offered, and nothing to fill. There is a reading of the research, organized and cited.

How we read the evidence

The method is consistent across every page: lead with what a study measured, attribute it to the source, and keep the strength of the evidence visible. Where sermorelin's own data is strong — the pediatric height-velocity result ^[1], the older-men GH/IGF-1 reversal ^[2], the pharmacokinetics ^[3] — we say so plainly. Where the popular claims outrun the sermorelin-specific record — adult anti-aging, weight loss, muscle — we mark the gap and name the related-analog or class-level studies that the claims actually rest on ^[5][6]. The goal is a reader who finishes more accurately informed, not more sold.

Regulatory and approval history

Sermorelin's regulatory history is frequently misstated, so this site states it carefully. Sermorelin acetate was an FDA-approved prescription drug for the evaluation and treatment of growth-hormone deficiency and short stature in children. It was withdrawn from the US market in 2008 for commercial reasons — not because of any safety or efficacy problem ^[5]. It is therefore neither a currently-marketed approved finished drug nor a compound that was "never approved": it is a formerly approved GHRH analog, now prepared by compounding pharmacies and treated as a long-standing Category 1 bulk drug substance under FDA's Section 503A framework (final guidance January 2025). This site does not provide regulatory, legal, or medical guidance; this paragraph is a factual summary, and the framing throughout is research-digest, not clinical.

What we do not do

We do not sell sermorelin, recommend a dose, or tell anyone to use it. We do not name vendors or sources of supply. We do not invent authors or clinicians, claim a clinic location, or imply a treatment relationship. Quantitative claims map to the numbered references; where the literature is silent or thin, we say so rather than filling the gap. Sermorelin is prohibited in sport (WADA S2) ^[8], and that, like every other regulatory fact here, is reported as context — not advice.